Purpose: evaluate the eff ects of DPP4i on fasting and postprandial insulin and glucagon secretion by examining basal secretion and response to food loading.Materials and methods: patients (n = 54) were divided into treatment groups: long-term (more than a year) therapy with iDPP4 with Metformin, Metformin + sulfonylurea, fi rst-time therapy with iDPP4. Biochemical parameters, levels of insulin, glucagon, C-peptide before and aft er a standard breakfast were measured. Th e HOMA IR and HOMA β indices were calculated. Results: we obtained a signifi cant diff erence in fasting glucagon and insulin levels between the iDPP4 over a year and Metformin + SM groups. In addition, insulin levels before and aft er standard breakfast, C-peptide aft er standard breakfast, and fasting glucagon decreased aft er 6 months of fi rst-time DPP4 therapy.Summary: the data obtained indicate the ability of iDPP4 to positively infl uence the two earliest and most signifi cant links in the pathogenesis of type 2 diabetes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.